While market jitters have kept some IPO candidates on the sidelines, biotechs continue to tap the public market, with two ...

The Cambridge, Massachusetts company is offering 9.72 million shares at $17 to $19 each and plans to list on Nasdaq under the ...

Oct 9 (Reuters) - City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech companies press ahead with listings despite market ...

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on ...

Max Darrow reports.

Steven Quay, a biopharmaceutical executive with no background in infectious diseases, is no longer being considered for ...

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the ...

The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks ...

Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...

WASHINGTON — A broad tariff on imported pharmaceuticals took effect at the end of September, and some biopharma companies and ...

Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.